Keto-acid therapy in predialysis chronic kidney disease patients: consensus statements.
D.F. belongs to the Fresenius Kabi Ketoanalogue Advisory Board, and has received travel grants and consultancy fees. M.A., N.C., A.C., T.E., L.G., and G.Z. participated as speakers at the 4th International Advisory Board Meeting Ketosteril , Marseilles, France, June 15 and 16, 2008, and received a consultancy fee from Fresenius Kabi for their participation. H.-H.L. and V.T. also received a consultancy fee from Fresenius Kabi for participating in the Advisory Board. This article was published as part of a supplement sponsored by an unrestricted educational grant from Fresenius Kabi. 2009 by the National Kidney Foundation, Inc. All rights reserved. 1051-2276/09/1905S-0012$36.00/0 doi:10.1053/j.jrn.2009.06.013